Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Oct;18(4):446-69.
doi: 10.1007/s10985-012-9224-6. Epub 2012 Jul 19.

Robust inference in discrete hazard models for randomized clinical trials

Affiliations

Robust inference in discrete hazard models for randomized clinical trials

Vinh Q Nguyen et al. Lifetime Data Anal. 2012 Oct.

Abstract

Time-to-event data in which failures are only assessed at discrete time points are common in many clinical trials. Examples include oncology studies where events are observed through periodic screenings such as radiographic scans. When the survival endpoint is acknowledged to be discrete, common methods for the analysis of observed failure times include the discrete hazard models (e.g., the discrete-time proportional hazards and the continuation ratio model) and the proportional odds model. In this manuscript, we consider estimation of a marginal treatment effect in discrete hazard models where the constant treatment effect assumption is violated. We demonstrate that the estimator resulting from these discrete hazard models is consistent for a parameter that depends on the underlying censoring distribution. An estimator that removes the dependence on the censoring mechanism is proposed and its asymptotic distribution is derived. Basing inference on the proposed estimator allows for statistical inference that is scientifically meaningful and reproducible. Simulation is used to assess the performance of the presented methodology in finite samples.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Replicated progression-free survival curves for the Atrasentan phase 2 trial based on simulated data
Fig. 2
Fig. 2
Illustration of the censoring-dependence and maximum observable time. a shows the survival curves for two groups exhibiting nonproportional hazards over the support [0,3]. b shows the survival curves for the same two groups over the support over [0,1]. c shows varying densities for the censoring times that correspond to different estimands in d
Fig. 3
Fig. 3
Survival curves of the different scenarios under consideration for the simulation study. Solid line indicates the control group and dotted line indicates the treatment group
Fig. 4
Fig. 4
Different censoring distributions, SC (· | R), under consideration for the simulation study. Case 1 is that of C = ∞ and administrative censoring occurs at t = 4

Similar articles

Cited by

References

    1. Abbott Laboratories. Oncologic drugs advisory committee: briefing document for atrasentan (Xinlay™) 2005 URL: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4174B1_01_01-Abbott....
    1. Bennett S. Analysis of survival data by the proportional odds model. Stat Med. 1983;2:273–277. - PubMed
    1. Berridge DM, Whitehead J. Analysis of failure time data with ordinal categories of response. Stat Med. 1991;10:1703–1710. - PubMed
    1. Boyd AP, Kittelson JM, Gillen DL. Estimation of treatment effect under non-proportional hazards and conditionally independent censoring. Stat Med. 2012 doi: 10.1002/sim.5440. - DOI - PMC - PubMed
    1. Breslow N. Covariance analysis of censored survival data. Biometrics. 1974;30:89–99. - PubMed

Publication types

MeSH terms